This is a heavily interactive web application, and JavaScript is required. Simple HTML interfaces are possible, but that is not what this is.
Post
IDSA
idsainfo.bsky.social
did:plc:kzhajznovzxkzzmpckix6yub
On IDSA’s & HIVMA’s Science Speaks blog: Christopher J. Graber, MD, MPH, FIDSA, explores dalbavancin versus standard therapy for completion of treatment of complicated S. aureus bacteremia. https://bit.ly/4ncqnAt
https://www.idsociety.org/science-speaks-blog/2025/dot-ting-is-and-crossing-ts-more-evidence-for-using-long-acting-glycopeptides-to-finish-therapy-of-complicated-s.-aureus-bacteremia
2025-10-17T00:43:03.766Z